(VIANEWS) – Star Bulk Carriers Corp. (SBLK), Neurocrine Biosciences (NBIX), John Bean Technologies Corporation (JBT) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Star Bulk Carriers Corp. (SBLK)

81% sales growth and 12.98% return on equity

Star Bulk Carriers Corp., a shipping company, engages in the ocean transportation of dry bulk cargoes worldwide.

Star Bulk Carriers Corp.’s sales growth this year is anticipated to be 62.3% and 2.6% for next year.

Year-on-year quarterly revenue growth grew by 113.1%, now sitting on 898.12M for the twelve trailing months.

Volume

Today’s last reported volume for Star Bulk Carriers Corp. is 2059920 which is 8.93% below its average volume of 2262000.

Star Bulk Carriers Corp.’s sales growth is a negative 0% for the current quarter and 81% for the next. The company’s growth estimates for the ongoing quarter and the next is 639.3% and 460%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.98%.

Volatility

Star Bulk Carriers Corp.’s last day, last week, and last month’s current intraday variation average was 2.03%, 4.71%, and 2.83%, respectively.

Star Bulk Carriers Corp.’s highest amplitude of average volatility was 4.58% (day), 6.39% (last week), and 5.32% (last month), respectively.

Star Bulk Carriers Corp.’s Stock Yearly Top and Bottom Value

Star Bulk Carriers Corp.’s stock is valued at $21.66 at 15:22 EST, way under its 52-week high of $26.00 and way above its 52-week low of $7.55.

Star Bulk Carriers Corp.’s Moving Average

Star Bulk Carriers Corp.’s worth is above its 50-day moving average of $21.28 and above its 200-day moving average of $19.75.

2. Neurocrine Biosciences (NBIX)

30.2% sales growth and 42.19% return on equity

Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders.

Neurocrine Biosciences’s sales growth this year is expected to be 9% and 23.4% for next year.

Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 1.05B for the twelve trailing months.

Volume

Today’s last reported volume for Neurocrine Biosciences is 775507 which is 8.85% above its average volume of 712428.

Neurocrine Biosciences’s sales growth for the next quarter is 30.2%. The company’s growth estimates for the present quarter and the next is 193.5% and negative -80.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.19%.

Volatility

Neurocrine Biosciences’s last day, last week, and last month’s current intraday variation average was 1.20%, 1.77%, and 1.25%, respectively.

Neurocrine Biosciences’s highest amplitude of average volatility was 3.02% (day), 4.63% (last week), and 3.36% (last month), respectively.

Neurocrine Biosciences’s Stock Yearly Top and Bottom Value

Neurocrine Biosciences’s stock is valued at $79.68 at 15:22 EST, way under its 52-week high of $120.27 and higher than its 52-week low of $79.01.

Neurocrine Biosciences’s Moving Average

Neurocrine Biosciences’s value is way below its 50-day moving average of $95.40 and way under its 200-day moving average of $95.52.

3. John Bean Technologies Corporation (JBT)

22.8% sales growth and 17.19% return on equity

John Bean Technologies Corporation provides technology solutions to food and beverage industry and equipment and services to air transportation industries.

John Bean Technologies Corporation’s sales growth this year is expected to be 12% and 10.4% for next year.

Year-on-year quarterly revenue growth declined by 8.7%, now sitting on 1.69B for the twelve trailing months.

Volume

Today’s last reported volume for John Bean Technologies Corporation is 305635 which is 91.36% above its average volume of 159716.

John Bean Technologies Corporation’s sales growth for the next quarter is 22.8%. The company’s growth estimates for the present quarter and the next is 45.8% and 46.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.19%.

Volatility

John Bean Technologies Corporation’s last day, last week, and last month’s current intraday variation average was 0.94%, 0.96%, and 1.71%, respectively.

John Bean Technologies Corporation’s highest amplitude of average volatility was 3.44% (day), 2.59% (last week), and 3.28% (last month), respectively.

John Bean Technologies Corporation’s Stock Yearly Top and Bottom Value

John Bean Technologies Corporation’s stock is valued at $1.16 at 15:22 EST, way below its 52-week low of $110.53.

John Bean Technologies Corporation’s Moving Average

John Bean Technologies Corporation’s worth is way below its 50-day moving average of $155.91 and way under its 200-day moving average of $143.88.

4. Kemper Corporation (KMPR)

16.5% sales growth and 6.6% return on equity

Kemper Corporation, a diversified insurance holding company, provides property and casualty, and life and health insurance in the United States.

Kemper Corporation’s sales growth this year is anticipated to be 16.8% and 7.5% for next year.

Year-on-year quarterly revenue growth grew by 21.6%, now sitting on 5.58B for the twelve trailing months.

Volume

Today’s last reported volume for Kemper Corporation is 252195 which is 0.76% above its average volume of 250274.

Kemper Corporation’s sales growth for the next quarter is 16.5%. The company’s growth estimates for the ongoing quarter and the next is a negative 66.9% and negative -44%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.6%.

Volatility

Kemper Corporation’s last day, last week, and last month’s current intraday variation average was 2.10%, 1.26%, and 1.74%, respectively.

Kemper Corporation’s highest amplitude of average volatility was 2.99% (day), 2.42% (last week), and 2.98% (last month), respectively.

Kemper Corporation’s Stock Yearly Top and Bottom Value

Kemper Corporation’s stock is valued at $-0.20 at 15:22 EST, way below its 52-week low of $56.76.

Kemper Corporation’s Moving Average

Kemper Corporation’s value is way below its 50-day moving average of $64.79 and way below its 200-day moving average of $71.85.

5. U.S. Physical Therapy (USPH)

8% sales growth and 15.52% return on equity

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

U.S. Physical Therapy’s sales growth this year is expected to be 16% and 6.1% for next year.

Year-on-year quarterly revenue growth grew by 51.1%, now sitting on 460.6M for the twelve trailing months.

Volume

Today’s last reported volume for U.S. Physical Therapy is 107205 which is 59.39% above its average volume of 67259.

U.S. Physical Therapy’s sales growth for the next quarter is 8%. The company’s growth estimates for the current quarter and the next is a negative 9.4% and negative -11.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.52%.

Volatility

U.S. Physical Therapy’s last day, last week, and last month’s current intraday variation average was 1.70%, 1.96%, and 2.27%, respectively.

U.S. Physical Therapy’s highest amplitude of average volatility was 5.57% (day), 3.52% (last week), and 3.90% (last month), respectively.

U.S. Physical Therapy’s Stock Yearly Top and Bottom Value

U.S. Physical Therapy’s stock is valued at $84.54 at 15:22 EST, way below its 52-week high of $143.67 and higher than its 52-week low of $84.43.

U.S. Physical Therapy’s Moving Average

U.S. Physical Therapy’s worth is way below its 50-day moving average of $104.78 and way under its 200-day moving average of $112.68.

LEAVE A REPLY

Please enter your comment!
Please enter your name here